vandetanib Articles
US FDA delays AstraZeneca’s vandetanib NDA for three months; combo diabetes drug Kombiglyze launched
10 January 2011
US FDA advisory panel backs approval of AstraZeneca’s thyroid cancer drug vandetanib
3 December 2010
AstraZeneca prostate cancer drug fails in Phase III trial
28 September 2010
US FDA and EMEA accepts AstraZeneca’s filing for vandetanib; SOBI gains orphan status for hemophilia A therapy in EU
23 September 2010
Strong data on AstraZeneca’s vandetanib in advanced papillary or follicular thyroid cancer; FDA clears new Faslodex dosage
13 September 2010
Showing 1-9 of 9 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
